Navigation Links
Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease
Date:12/7/2007

Event to Feature 'Kidney-Friendly' Recipes

HOUSTON, Dec. 7 /PRNewswire-FirstCall/ -- Celebrity chef Katie Lee Joel and Shire Pharmaceuticals (Nasdaq: SHPGY), the global biopharmaceutical company, today announced that Katie will be conducting a free cooking demonstration at the Doubletree Hotel Houston Downtown from 1-3 PM tomorrow, Saturday, December 8th, for local patients with chronic kidney disease (CKD) and their families.

During the demonstration, Katie will demonstrate to patients and their family members how to prepare recipes from Shire's 2007 edition of the Kidney Friendly Comfort Foods cookbook. Additionally, attendees will be able to sample some of Katie's recipes, as well as receive a complimentary copy of the new cookbook, which will be available for free after the event, by visiting http://www.FOSRENOL.com or by calling (866) 896-6152.

Kidney disease is an issue close to Katie's heart because her grandfather was a dialysis patient for several years. Although the family was worried about his health, her grandfather was more concerned with the restrictions the condition put on his diet. To help keep him healthy and happy, Katie and her grandmother adapted many of their family's traditional recipes so that Katie's grandfather and the rest of the family could still eat the meals that they loved.

"I know how difficult managing kidney disease can be, which is why I was so excited to contribute my recipes to Shire's second volume of the Kidney Friendly Comfort Foods cookbook," said Katie. "It's especially important for CKD patients to have holiday recipes that meet their dietary needs, so that they don't feel left out
'/>"/>

SOURCE Shire Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
2. The next generation: nanomagnets could replace semiconductors
3. IBM and Imago find a crucial difficulty in semiconductor device scaling
4. Doping technique brings nanomechanical devices into the semiconductor world
5. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
6. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
7. New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays
8. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 In a ... industry suppliers will present technologies with applications in ... annual SPIE Optics and Photonics symposium ... SPIE, the international society for optics and ... multidisciplinary optical sciences and technology meeting in North ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... up to ... $385 million plus royalties -, PALO ALTO, ... announced today that it has entered into an agreement,granting exclusive ... countries to the Menarini Group. Menarini,with its significant pan-European presence, ...
... Management,Slate of InSite Vision, Including the Chairman and ... Sept. 11 PTV Sciences,("PTV"), a healthcare venture ... that RiskMetrics Group -(Formerly known as ISS), the ... that the,stockholders of InSite Vision Incorporated (Amex: ...
... 11 A project to advance,research and improve ... by a,new $1.6 million, three-year cooperative agreement with ... The agreement, intended to bring better care to ... National Fragile X Foundation (NFXF),the CDC,s National Center ...
Cached Biology Technology:CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 2CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 3CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 5RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 2RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 3RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 4$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope 2
(Date:5/24/2013)... combat metastatic cancer , Cancer cells spread and ... system. Stimulation of the immune system can help to ... cause the immune system to ignore cancer cells. Regulatory ... the immune system response. In this issue of the ... Ronald Levy at Stanford University found that regulatory T ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
(Date:5/23/2013)... National Laboratory honored more than 165 staff for ... at PNNL,s annual Intellectual Property Commercialization Recognition & ... Energy national laboratory named materials scientist Jun Liu ... battery materials that can store large amounts of ... reduce the time it takes to charge cell ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... , DNA-Prokids ( http://www.dna-prokids.org ), an international project ... victims and their relatives, was officially presented today, at the ... Traffic in human beings is one of the most ... century. According to data from the United Nations Office on ...
... rapid growth of institutional Memberships for open access ... of the "Online Reporting System" for its open ... BioMed Central,s cutting edge publishing platform, the new ... and help reduce the administrative costs associated with ...
... Stedim Biotech (SSB) and Adolf Kühner AG ,- Prototype ... ,Monthey, 19. Mai 2009 / b3c newswire ... to the biopharmaceutical industry, expands its product offering with ... OrbShake bioreactors rely on orbital shaking principles for ...
Cached Biology News:DNA-Prokids: Genetic identification against traffic in human beings 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3
... Clone/PAD: ZMD.460. Immunogen: Synthetic ... the human C35 protein (chromosome 17 open ... Specificity: Specific for the C35 protein. ... band at ~15 kDa band. Reactivity: ...
...
... Peptide sequences: Two ... peptide corresponding to the same sequence ... polyclonal antiserum (Catalog No. 160890) ... conjunction with Cayman's guanylate cyclase polyclonal ...
... Calmodulin Sepharose ... For single-step purification ... fusion proteins.Purification of ... all eukaryotic cells. ...
Biology Products: